Back

Vascular dysfunction is associated with symptom severity and quality of life in wild-type transthyretin amyloid cardiomyopathy

30 August 2026 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: New insights into cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Nobuhiro Ogasawara

Akita University Graduate School of Medicine, Akita (Japan)

6 More presentations in this session

Presentation thumbnail
Decoding peripartum cardiomyopathy through multi-omics: circulating and cellular signatures from the Italian multicenter registry
Doctor M. Carotenuto (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Diagnostic utility of three clinical scoring systems for transthyretin amyloid cardiomyopathy in elderly Asian patients with heart failure with preserved ejection fraction
Doctor M. Chen (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Improvement of health status with acoramidis in patients with wild-type and variant transthyretin amyloid cardiomyopathy: KCCQ domains analysis from the ATTRibute-CM study
Doctor N. Sarswat (Chicago, US)
Abstract Slides Video
Presentation thumbnail
Acoramidis improves health-related quality of life in wild-type and variant transthyretin amyloid cardiomyopathy: An EQ-5D-5L subgroup analysis from ATTRibute-CM
Doctor E. Joyce (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
Which therapy performs best across clinical domains in transthyretin amyloid cardiomyopathy? a frequentist network meta-analysis
Mr A. Calderon Fernandez (Tijuana, MX)
Abstract Slides Video

Access the full session

Session thumbnail
New insights into cardiac amyloidosis

The Event

Event poster

ESC Congress 2026

30 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Structural and functional echocardiographic characterisation and prognostic determinants in real-world transthyretin amyloid cardiomyopathy patients on standard of care
31 August 2026
thumbnail
Congress Presentation
Prevalence and determinants of coronary microvascular dysfunction as assessed by bolus intracoronary thermodilution in patients with wild type transthyretin amyloidosis cardiomyopathy
31 August 2025
thumbnail
Congress Presentation
Exercise hemodynamics and mitochondrial oxidative capacity in disease stages of wild-type transthyretin amyloid cardiomyopathy.
11 May 2024
thumbnail
Congress Presentation
Clinical impact of atrial fibrillation on cardiac parameters and long-term outcomes in patients with transthyretin amyloid cardiomyopathy in the era of disease-modifying therapy
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources